| Title |
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b
|
|---|---|
| Published in |
Journal of Neurology, November 2007
|
| DOI | 10.1007/s00415-007-0733-2 |
| Pubmed ID | |
| Authors |
C. Polman, L. Kappos, M. S. Freedman, G. Edan, H.-P. Hartung, D. H. Miller, X. Montalbán, F. Barkhof, K. Selmaj, B. M. J. Uitdehaag, S. Dahms, L. Bauer, C. Pohl*, R. Sandbrink*, for the BENEFIT investigators** |
| Abstract |
The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions. Subgroups of 468 patients (IFNB-1b: n = 292; placebo: n = 176) were created for demographics, clinical, laboratory, and MRI findings at onset. The 'natural' risk of clinically definite MS (CDMS) over 2 years was estimated by Kaplan Meier statistics in placebo-treated patients; the IFNB-1b treatment effect was analysed by Cox proportional hazards regression. The risk of CDMS was increased in placebo-treated patients (overall 45 %) if they were younger (< 30 years: 60%), were cerebrospinal fluid (CSF)-positive (49 %), or had received steroid treatment (48 %). MRI parameters implied a higher risk in placebo-treated patients with > or = 9 T2-lesions (48%) or > or = 1 gadolinium (Gd)-enhancing lesions (52 %). The CDMS risk was highest (75 %) in placebo-treated patients with monofocal disease onset displaying MRI disease activity (> or = 1 Gd-lesion) and dissemination (> or = 9 T2-lesions). Treatment effects were significant across almost all subgroups including patients with less disease dissemination/activity at onset (monofocal: 55%; < 9 T2-lesions: 60%; no Gd-lesions: 57%) and patients without steroid treatment for the CIS (62 %). Monofocal patients had greater treatment effects if they had > or = 9 T2-lesions (61 %), Gd-lesions (58 %), or both (65 %). This study confirms the impact of age of onset, CSF and MRI findings on risk of conversion from CIS to CDMS. IFNB-1b treatment effect was robust across the study population including patients without MRI disease activity and less clinical or MRI disease dissemination at onset and patients not receiving steroids for the CIS. |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Egypt | 1 | 1% |
| Unknown | 82 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 14% |
| Researcher | 12 | 14% |
| Professor | 10 | 12% |
| Other | 7 | 8% |
| Student > Master | 6 | 7% |
| Other | 27 | 32% |
| Unknown | 10 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 52% |
| Neuroscience | 8 | 10% |
| Agricultural and Biological Sciences | 6 | 7% |
| Psychology | 3 | 4% |
| Unspecified | 2 | 2% |
| Other | 5 | 6% |
| Unknown | 16 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 September 2015.
All research outputs
#4,179,915
of 22,828,180 outputs
Outputs from Journal of Neurology
#999
of 4,477 outputs
Outputs of similar age
#12,301
of 76,146 outputs
Outputs of similar age from Journal of Neurology
#3
of 20 outputs
Altmetric has tracked 22,828,180 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,477 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 76,146 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.